PDL BioPharma Inc. (PDLI)

2.60
0.03 1.17
NASDAQ : Health Technology
Prev Close 2.57
Open 2.60
Day Low/High 2.57 / 2.65
52 Wk Low/High 2.25 / 3.89
Volume 1.36M
Avg Volume 1.04M
Exchange NASDAQ
Shares Outstanding 114.20M
Market Cap 292.36M
EPS -0.50
P/E Ratio 8.62
Div & Yield N.A. (N.A)
Cramer's 'Mad Money' Recap: The Next Great Diagnostics Play

Cramer's 'Mad Money' Recap: The Next Great Diagnostics Play

It's Cepheid, a small company in the running for a big government contract.

Weekend Blog Watch

A tasty options cocktail, how to be a hit at parties and why global ETFs are overbought.

Wednesday's Health Winners & Losers

Avalon Pharmaceuticals is rising.

Friday's Health Winners & Losers

Friday's Health Winners & Losers

Gene Logic is falling.

Thursday's Health Winners & Losers

PDL BioPharma is higher.

Thursday's Early Winners & Losers

Thursday's Early Winners & Losers

Whole Foods rallies after announcing it will buy Wild Oats.

PDL Ends Marketing Deal

The company gives up rights to a proposed kidney drug.

Friday's Health Winners & Losers

Pharmaxis shares surge after the FDA grants the company's cystic fibrosis drug fast-track status.

Wednesday's Health Winners & Losers

Tenet Healthcare is rising.

Wednesday's Early Winners & Losers

Wednesday's Early Winners & Losers

Dell soars as its earnings beat Wall Street estimates.

Roche Ends PDL BioPharma Pact

It pulls out of a collaboration agreement.

PDL's Sales Top Estimates

Its quarterly loss narrows year over year.

Wednesday's Health Winners & Losers

Wednesday's Health Winners & Losers

Adeza and Merge are higher.

PDL BioPharma Rights Plan

PDL BioPharma Rights Plan

It seeks to scare off hostile bidders.

PDL Just Got Riskier

Because of setbacks in the company's pipeline, investors should exercise caution.

PDL Drug Trial Falls Short

PDL Drug Trial Falls Short

Separately, the company's adjusted earnings top estimates.

PDL Looks for a Push

PDL Looks for a Push

Investors need to know that its earnings and pipeline are moving in the right direction.

Monday's Health Winners & Losers

Monday's Health Winners & Losers

Elan rises, but Beckman Coulter is weaker.

Today's Health Winners and Losers

Cigna's weak guidance pulls down shares.

PDL BioPharma Crushed

The stock drops 26% after a first-quarter earnings shortfall.

Today's Early Winners and Losers

Advanced Digital soars after agreeing to be bought out by Quantum.

PDL BioPharma Adds Director

Brad Goodwin comes aboard.

PDL BioPharma Names CFO

PDL BioPharma Names CFO

Andrew Guggenhime joins from Neoforma.

PDL BioPharma Loss Widens

Revenue more than triples.

Today's Early Winners and Losers

Today's Early Winners and Losers

Shanda Interactive tanks after its fourth-quarter results fall short of estimates.

Key Events Nearing for Biogen Idec, but Upside Looks Limited

Key Events Nearing for Biogen Idec, but Upside Looks Limited

Expect the company to focus on relaunching Tysabri and extending Rituxan this quarter.

Health Stocks in Motion

Protein Design and Allergan are moving.

Swing Into Biotech With Eight Picks

Swing Into Biotech With Eight Picks

Members of this long watch list could be top performers in the weeks ahead.

Swing Into Biotech With Eight Picks

Members of this long watch list could be top performers in the weeks ahead.

Early Stocks in Motion

Early Stocks in Motion

Adobe beats estimates.

TheStreet Quant Rating: C- (Hold)